TSR-033

• CAT Number: I042210
• CAS Number: 2225940-96-3
• Purity: ≥95%

TSR-033 is a high affinity human IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), a co-receptor associated with impaired T cell function and often co-expressed with PD-1, that enhances T cell function and PD-1 blocking activity in vitro and in vivo. TSR-033 has anti-tumor activity[1].
TSR-033 (0.01-1000 nmol/L, 48 h) increases IL2 production by primary human CD4 T cells and dendritic cells and enhanced T cell effector function[1].
TSR-033(i.p.,10 mg/kg, twice weekly, 40 days) has a moderate inhibitory effect on tumor growth with a TGI of 23% at termination by treatment with alone, while the combination with TSR-042 had a cumulative effect, impeding tumor growth to a greater extent, with a TGI of 45% at termination in A549 HuNOG-EXL NSCLC mice tumor model[1].

Reference

[1]. Srimoyee Ghosh, et al. TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo. Mol Cancer Ther. 2019 Mar;18(3):632-641.
 [Content Brief]